Results 131 to 140 of about 690,120 (348)

SPARCL1 and NT‐proBNP as biomarkers of right ventricular‐to‐pulmonary artery uncoupling in pulmonary hypertension

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 1416-1426, April 2025.
Abstract Aims SPARCL1 was recently identified as a biomarker of right ventricular (RV) maladaptation in patients with pulmonary hypertension (PH), and N‐terminal pro‐brain natriuretic protein (NT‐proBNP) is an established biomarker of RV failure in PH. The present study investigated whether NT‐proBNP and SPARCL1 concentrations are associated with load ...
Oliver Dörr   +15 more
wiley   +1 more source

Clinical utility and safety of finerenone in patients with heart failure: Rationale and design of FINE registry

open access: yesESC Heart Failure, EarlyView.
Abstract Aims Information about current use of finerenone in patients with heart failure (HF) finerenone in clinical practice is scarce, and its effectiveness in clinical practice in patients is scarce. We aim to assess both the baseline clinical profile and prognostic role of finerenone in patients with HF, irrespective of ejection fraction.
Gonzalo Luis Alonso Salinas   +32 more
wiley   +1 more source

Prognostic implications of functional tricuspid regurgitation in asymptomatic degenerative mitral regurgitation

open access: yesESC Heart Failure, EarlyView.
Abstract Aims Functional tricuspid regurgitation (FTR) associated with degenerative mitral regurgitation (DMR) accentuates the severity of heart failure and is a marker of poor prognosis. Little is known about FTR associated with asymptomatic DMR. Methods and results The study included 1249 asymptomatic patients with moderate or severe DMR from the ...
Christophe Tribouilloy   +16 more
wiley   +1 more source

Prescription of guideline‐directed medical therapy in heart failure: impact on mortality and readmission

open access: yesESC Heart Failure, EarlyView.
Routine data analysis showing a better outcome regarding mortality and readmission in HF patients when being prescribed the current four‐drug treatment (vs. the outdated two‐drug therapy) 91–365 days after index hospital stay. Abstract Aims The 2021 European heart failure (HF) guidelines recommend the combination of four drugs as a standard therapy ...
Martin Möckel   +9 more
wiley   +1 more source

Geometric description for the anatomy of the mitral valve: A review

open access: yesJournal of Anatomy, 2020
D. Oliveira   +5 more
semanticscholar   +1 more source

Exploring heart failure prevalence and dimensions: A comprehensive NT‐proBNP study in high‐risk primary care patients

open access: yesESC Heart Failure, EarlyView.
The diagnostic pathway of high‐risk primary care patients through NT‐proBNP. Abstract Introduction Early detection of heart failure (HF), particularly in asymptomatic individuals, is essential for timely intervention. This study aimed to determine the prevalence of HF among high‐risk individuals in primary care using N‐terminal probrain natriuretic ...
Ahmet Celik   +17 more
wiley   +1 more source

Plasma volume status predicting clinical outcomes in patients undergoing transcatheter edge‐to‐edge mitral valve repair

open access: yesESC Heart Failure, EarlyView.
Abstract Aims Plasma volume status (PVS) is recognized as a marker of systemic congestion, but its clinical utility in patients with mitral regurgitation (MR) undergoing transcatheter edge‐to‐edge mitral valve repair (M‐TEER) has not been well established. This study aimed to evaluate the prognostic significance of PVS in these patients.
Ai Kagase   +30 more
wiley   +1 more source

Prosthetic Replacement of the Mitral Valve [PDF]

open access: bronze, 1967
Andrew G. Morrow   +3 more
openalex   +1 more source

Home - About - Disclaimer - Privacy